162 results about "Lipid composition" patented technology

The invention relates to a dialkyl imidazole bionic lipid compound and a preparation method and application thereof.The structure of the dialkyl imidazole bionic lipid compound imitates natural phospholipid design, alkyl with no less than 10 carbon atoms is modified on the fourth site and the fifth site of imidazole, and primary amines with different alkyl chain lengths are modified on the second site; the dialkyl imidazole bionic lipid compound is mixed with a therapeutic drug and other auxiliary materials to prepare lipid nanoparticles loaded with the therapeutic drug, and the lipid nanoparticles can be used as a drug delivery system for preparation of brain-targeted drugs. The dialkyl imidazole bionic lipid has the function of dynamically regulating and controlling the blood-brain barrier, and can realize reversible opening of the blood-brain barrier; the formed drug-loaded lipid composition can pass through a blood brain barrier and well realize brain-targeted delivery of loaded therapeutic drugs; the drug-loaded lipid composition composed of the dialkyl imidazole bionic lipid belongs to a new generation of bionic nano-drug carriers, and provides a new strategy for realizing brain-targeted delivery of different types of drugs.

The present application relates to a kind of dihydrocarbylimidazole biomimetic lipid compound and its preparation method and application, dihydrocarbylimidazole biomimetic lipid compound structure imitates natural phospholipid design, modification is not less than 10 carbon atoms alkyl on the 4th and 5th of imidazole, and modification is different alkyl chain length primary amine on 2nd position;Dihydrocarbylimidazole biomimetic lipid compound is mixed with therapeutic drug and other adjuvant, can be prepared to be loaded in the lipid nanoparticle of therapeutic drug, can be used as drug delivery system for the preparation of brain-targeted drug.Dihydrocarbylimidazole biomimetic lipid has the function of dynamic control blood-brain barrier, can realize the reversible opening of blood-brain barrier;Formed drug-loaded lipid composition can cross blood-brain barrier and better realize the brain-targeted delivery of loaded therapeutic drug;Drug-loaded lipid composition consisting of dihydrocarbylimidazole biomimetic lipid belongs to a new generation of biomimetic nanomedicine carrier, provides new strategy for realizing the brain-targeted delivery of different kinds of drugs.

The invention relates to the technical field of cosmetics, and discloses an anti-inflammatory soothing cosmetic composition which comprises the following components in percentage by weight: 0.5%-4% of a barrier repairing component, 0.5%-3% of an immunoregulation component, 0.3%-2.5% of a nerve soothing component, 0.3%-3% of an anti-inflammatory plant compound, 1%-10% of a moisturizing soothing enhancer and the balance of auxiliary materials. According to the components, through a five-dimensional synergistic mechanism of barrier repair, immune tolerance, nerve desensitization, anti-inflammatory itching relieving, moisturizing and stability maintaining, anti-inflammatory relieving and barrier repair are remarkably enhanced; ceramide, rare ginsenoside, phytosterol ester and free fatty acid are introduced to synergistically construct a bionic liposome which is closer to the composition of human cuticle lipid, so that the transdermal absorption and stability are enhanced, and the repair efficiency is remarkably improved; the dipotassium glycyrrhizinate, the tamarix chinensis flower extract, the purslane extract, the dinoflaxanthine and the baicalin cooperate to quickly resist inflammation and relieve itching and strengthen barrier repair, so that the composition is suitable for highly sensitive skin.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

This disclosure provides a lipid composition and methods of use thereof.

Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol, glucosylcholesterol; and modified by (b) ionizable lipids. The present disclosure also includes a method for preparing a modified lipid composition, the method comprises reconstituting (a) a structural component comprising one or more lipids selected from the group consisting of soybean-derived lipids, cardiolipin, sphingolipid, ceramide, glucosylceramide, lactosylceramide, galactosylcholesterol and / or glucosylcholesterol in the presence of (b) ionizable lipids to produce the modified lipid composition, and loading one or more heterologous functional agents into the modified lipid composition.

Provided herein are methods and materials for using organisms (e.g., engineered yeast strain-derived) to generate lipid compositions which can modulate cellular aging, extend lifespan, and / or modulate gut homeostasis in a subject. The lipid compositions contain at least twelve of the lipids selected from a phosphatidylethanolamine (PE); a lysophosphatidylethanolamine (LPE); a diacylglycerol (DG); a monoglyceride (MG); an acyl carnitine (AcCa); a phosphatidic acid (PA); a phosphatidylglycerol (PG); a lysophosphatidylcholine (LPC); a triacylglycerol (TG); a cholesterol ester (ChE); a wax ester (WE); a phosphatidylserine (PS); a phosphatidylcholine (PC); a phosphatidylinositol (PI); a ceramide (Cer); and a lysophosphatidylserine (LPS).

Disclosed herein are aspects of a compound according to Formula (I) Y[-Z-Ao-X]y. The compound may have a structure according to Formula (II) or Formula (III). Also disclosed are compositions comprising the compounds that may be useful for delivering agents such as therapeutic and / or prophylactic agents, for example, nucleic acids such as, but not limited to, DNA or RNA, small molecules, proteins, polypeptides or peptides. In some aspects, the composition is a lipid nanoparticle. Also disclosed herein are lipid nanoparticles comprising the compounds and methods for making and using the nanoparticles.

Lipid composition comprising: (i) one or more cationic lipids, preferably cationically ionizable lipids, (ii) one or more phospholipids, and (iii) one or more statistical copolymers comprising repeating units of the following formula (I-a) and repeating units of formula (II-a) wherein R1 represents a hydrogen atom or a group selected from a C1-3 alkyl group, a cyclopropyl group, and a C3 alkenyl group; R2 represents a group selected from a saturated C4-40 hydrocarbyl group; an unsaturated C4-40 hydrocarbyl group having one or more carbon-carbon double and / or triple bonds; a saturated C4-40 heterohydrocarbyl group containing 1 to 5 divalent groups selected from ether, thioether, sulfone, sulfoxide, keto, ester, amide, carbamate and carbonate groups, and / or 1 to 5 fluorine atoms as substituents; and an unsaturated C4-40 heterohydrocarbyl group having one or more carbon-carbon double and / or triple bonds, and containing 1 to 5 divalent groups selected from ether, keto, ester, and carbonate groups and / or 1 to 5 fluorine atoms as substituents; and x and y independently represent 0 or 1.

The invention relates to a lipid composition, which comprises a polymer lipid, and the polymer lipid is a compound with a structure as shown in a formula (I), or a pharmaceutically acceptable salt, an isotope variant, a tautomer or a stereoisomer thereof. The invention also provides a nanoparticle composition and a pharmaceutical composition comprising the lipid composition, and an application of the lipid composition in delivery of a load. The polymer lipid compound in the lipid composition can replace PEG lipid and has the advantages of biocompatibility, easiness in decomposition in vivo and no toxicity, so that a novel lipid delivery system is obtained.

The invention relates to the field of synthetic biology, in particular to a structural lipid, a preparation method thereof, a structural lipid composition containing the structural lipid and used for protecting liver and eyes, and a product for protecting liver and eyes. The preparation method comprises the following steps: carrying out reaction on mixed oil and lipase, and carrying out enzyme deactivation to prepare structural lipid; wherein the weight ratio of omega3 fatty acid to omega6 fatty acid to omega9 fatty acid in the oil material is (0.8-1.2): (0.8-1.2): (0.8-1.2). The lipase is adopted to carry out hydrolysis reaction on appropriate oil, sn-2 site fatty acid with the liver and eye protection effect can be prepared, and the sn-2 site fatty acid is small in molecular weight and beneficial to absorption.

To provide a means effective in suppressing oxidative deterioration of fats and oils containing polyunsaturated fatty acid containing DHA and to provide a method capable of determining near olfactory sense of human being by specifying a component that becomes an index of oxidative deterioration of fat and acid containing DHA.SOLUTION: A lipid composition containing lipids composed of polyunsaturated fatty acids as constituent fatty acids, wherein a composition ratio of polyunsaturated fatty acids among all constituent fatty acids of the lipids is 15% or more, the moisture content is 600 ppm or less, perfluorooctanesulfonic acid is 0.1 ppb or less, and perfluorooctanoic acid is 0.1 ppb or less. It is preferable that the composition contains 2-(2-pentenyl)furan at less than 0.0095 ppm, and 2,4-heptadienal at less than 2.600 ppm.SELECTED DRAWING: None

Relates to a lipid composition with targeting property, the lipid composition comprises an active component, a lipid carrier and a targeting component, and the components of the lipid carrier comprise a positively charged component and phospholipid. An active component is entrapped in a lipid carrier containing a component with positive charges, so that the surface of the lipid carrier has positive charges, then the lipid carrier and a targeting component with negative charges are mixed, and the targeting component is adsorbed on the surface of the drug-loaded lipid carrier with positive charges through an electrostatic adsorption effect, so that the drug-loaded lipid carrier which is high in transfection efficiency and good in transfection effect is prepared. The present invention relates to a lipid composition having a targeting property and a high targeting property. The invention relates to a lipid nanoparticle delivery system with high biological activity, tumor targeting property and good safety. The lipid nanoparticle delivery system comprises an active component, cationic lipid, ionizable lipid and neutral phospholipid. The active component is entrapped in the lipid nanoparticle containing the cationic lipid, the ionizable lipid and the neutral phospholipid, and when the molar ratio of the cationic lipid to the ionizable lipid is in a specific range, the lipid nanoparticle has higher biological activity, tumor targeting property and good safety.

This application relates to the fields of chemistry and biomedicine, specifically to a tofenamic acid lipid composition, its preparation method, and its application. A tofenamic acid derivative is obtained by reacting a morpholine solution with tofenamic acid, ethyldimethylaminopropylcarbodiimide, and 4-dimethylaminopyridine, followed by purification. The morpholine in the morpholine solution is an N-alkylmorpholine compound. The tofenamic acid derivative is used to prepare tofenamic acid prodrug liposomes via ethanol injection, which are then used in combination with a STING agonist. The synergistic effect of the combined treatment stems from the dual regulation of the tumor immune microenvironment (TME), overcoming the immune escape induced by STING monotherapy. After STING agonist treatment, the intratumoral COX-2 / PGE2 axis is activated, leading to immunosuppression. The combination of tofenamic acid liposomes and a STING agonist inhibits COX-2, thus relieving this negative feedback loop.

The invention discloses a macrophage-targeting lipid nanoparticle and application thereof in malignant tumor treatment, ID3 mRNA is delivered through the lipid nanoparticle, firstly, an ID3 sequence is subjected to codon optimization to improve the expression efficiency and stability of ID3 protein, and the core treatment effect is enhanced; the lipid composition and the targeting ligand of the nanoparticles are further optimized, and mannose modified PEG lipid material (DSPE-PEG2000-Mannose) is specifically combined with the CD206 receptor on the surface of the macrophage, so that the targeting property and the transfection efficiency of the delivery system are remarkably improved. The ID3 mRNA is delivered to the macrophages by utilizing the lipid nanoparticles of the targeted macrophages, so that the tumor cells can be effectively swallowed and killed, the in-situ treatment of pancreatic cancer is realized, and better tumor inhibition and immune activation effects are achieved.

The present embodiments provide a plant-based lipid composition comprising high concentrations of long-chain omega-3 fatty acids, typically as fatty acid esters, comprising DPA, DTA, ETA, or ETrA, optionally with OA or ALA. These enriched lipid compositions have improved stability, and offer a sustainable source for these long-chain omega-3 fatty acids. In some embodiments, these enriched lipid compositions show enhanced modulation of inflammatory markers, such as inhibition of inflammatory cytokines, and offer nutritional or therapeutic value..

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present invention addresses the problem of providing: a compound or a salt thereof that is to constitute a lipid composition that makes it possible to achieve high expression of a protein when an mRNA is used and dose-responsive protein production when administered at a high dose; and a lipid composition, a pharmaceutical composition, and a delivery carrier that use the compound or salt thereof. The present invention provides a compound represented by formula (1) or a salt thereof. Each group in the formula is defined in the description.

The invention relates to a lipid composition for oral administration comprising a combination of medium-chain fatty acids and long-chain polyunsaturated fatty acids for use in the simultaneous, separate or sequential treatment of cystic fibrosis in a population of individuals at least 2 years of age, having at least one F508 (F508del) mutation in the transmembrane conductance regulator gene and undergoing treatment with CFTR protein modulating drugs.

The invention relates to the technical field of skin care, and discloses a sustained-release composition containing azelaic acid composite lipidosome and application of the sustained-release composition in acne treatment and skin repair. Comprising a composite liposome, an encapsulated active component and a dispersion medium, the composite liposome is composed of a lipid bilayer, the lipid bilayer comprises phospholipid, cholesterol and pegylated phospholipid, and the phospholipid is a mixture of hydrogenated soybean phospholipid and dipalmitoyl phosphatidylcholine; the encapsulated active component comprises a fat-soluble component and a water-soluble component; the water-soluble components comprise a hamamelis virginiana leaf water extract and a herba portulacae extract; the dispersion medium is a phosphate buffer solution; by optimizing lipid composition, introducing surface modification and constructing a multi-layer release system, the invention aims to synergistically exert multiple effects of antibiosis, anti-inflammation, cutin regulation, red fading, repair and the like, and provides an efficient, mild and integrated solution for acne and sequelae skin problems thereof.

The invention belongs to the technical field of biological medicines, and particularly discloses a pork liver source / photosensitizer-loaded pork liver source lipid nanoparticle and application thereof in endoplasmic reticulum stress enhanced phototherapy. The lipid extraction method provided by the invention has the advantages of mature process, low cost, easily available raw materials, clear components of the obtained lipid, and high biocompatibility. The pork liver source lipid nanoparticles prepared from natural lipid extracted from pork liver have good endoplasmic reticulum targeting property, and can be used as a carrier to efficiently load a photosensitizer IR780; the related nanoparticle preparation method is simple, good in repeatability and easy for expanded production. A phototherapy system constructed by the nanoparticles can generate active oxygen in situ in an endoplasmic reticulum under near-infrared laser irradiation to initiate strong endoplasmic reticulum stress, so that the anti-tumor effect of photothermal and photodynamic combined treatment is remarkably enhanced, and the nanoparticles can be widely applied to efficient and accurate treatment of various solid tumors.

It relates to a sweetened lipid composition, comprising: (a) from 30wt. % to 70wt. % of a lipid component, by weight of the lipid composition; (b) from 10wt. % to 40wt. % of a sweetening substance, by weight of the lipid composition; (c) from 15wt. % to 30 wt. % water, by weight of the lipid composition; (d) from 0.5 to 10 wt. % starch-based component, by weight of the lipid composition, a process for preparing it, its use in food products and the use of starch derivatives to capture water in the food products, preferably bakery product.

The invention provides UVB damage repair application of a grease composition containing safflower seed oil and fermented artemisia apiacea oil. The fermented artemisia apiacea oil is prepared by the following steps: (a) carrying out supercritical CO2 extraction on artemisia apiacea medicinal materials; (b) fermenting, namely fermenting by adopting bifidus yeast; (c) separating to obtain fermented artemisia apiacea oil; wherein the bifidobacterium is selected from bifidobacterium adolescentis, bifidobacterium animalis subspecies, bifidobacterium animalis subspecies lactis, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium longum subspecies longum or bifidobacterium longum subspecies infantis. The invention further relates to application of the grease composition containing the safflower seed oil and the fermented artemisia apiacea oil in preparation of a skin external preparation with a UVB damage repairing effect.

The invention provides a lipidosome adjuvant system based on furanose type QS-21 saponin molecules and a preparation method. The lipidosome adjuvant system comprises lipidosome and the QS-21 saponin molecules, the lipidosome comprises a lipid bilayer formed by ionizable lipid, structural phospholipid and cholesterol, the QS-21 saponin molecule is in a furanose type and is loaded on the lipidosome, and the QS-21 saponin molecule is partially inserted into the lipid bilayer through hydrophobic triterpenoid aglycone of the QS-21 saponin molecule. The preparation method comprises the following steps: dissolving lipidosome components forming lipid bilayers in an organic solvent to form a lipid phase, dissolving furanose type QS-21 saponin molecules in an acidic aqueous phase buffer solution to form a QS-21 aqueous phase, mixing the lipid phase and the QS-21 aqueous phase, precipitating lipid, and self-assembling to form lipidosome nanoparticles loaded with furanose type QS-21 saponin molecules, and finally, purifying to remove the organic solvent and the unencapsulated QS-21 molecules. According to the invention, through well-designed lipid composition and a preparation process, furanose type QS21 molecules are stably integrated into the lipidosome.

The invention relates to the field of medical biology, and discloses a lipid composition with improved liver targeting, a pharmaceutical composition containing the lipid composition and application of the lipid composition and the pharmaceutical composition. Aiming at the problems of complex synthesis process, low yield, poor targeting property, poor drug effect and the like of the existing liver targeting drug delivery system, the invention redesigns the formula of the LNP delivery system, and provides the drug targeting delivery system with good liver targeting property and low cytotoxicity by selecting specific types of lipids for matching. While side effects of liver injury and the like are reduced, a good curative effect is maintained, and a basis is provided for research, development and production of targeted biomolecular drugs.

The application discloses an oil and fat composition for resisting porcine enterovirus infection and application thereof. The oil and fat composition comprises at least two of glyceryl monopentanoate, glyceryl monolinoleate and glyceryl monomyristate. The oil and fat composition can further comprise anhydrous ethanol, propylene glycol, dimethyl sulfoxide, edible oil, Tween 80, lactose, mannitol, soluble starch, water and other auxiliary materials for preparing oil and fat composition preparations. The oil and fat composition can inhibit enterovirus through multiple channels and multiple levels, and improve the antiviral effect. Adding the oil and fat composition in the feed of pigs can not only improve the antiviral ability, but also reduce the inflammatory reaction caused by pathogenic infection through the anti-inflammatory and immune regulation effects, effectively prevent and treat the infection of porcine enterovirus diarrhea, and thus reduce the incidence of porcine enterovirus diarrhea and the mortality of pigs with the disease. The oil and fat composition can be used for preparing a medicine or a feed additive for treating and preventing porcine enterovirus diarrhea.

The present application relates to the field of cosmetic technology, and discloses an anti-inflammatory soothing cosmetic composition, which comprises the following components in percentage by weight: a barrier repair component: 0.5-4%, an immunomodulatory component: 0.5-3%, a nerve soothing component: 0.3-2.5%, an anti-inflammatory plant complex: 0.3-3%, a moisturizing soothing enhancer: 1-10%, and a balance of auxiliary materials. The above components significantly enhance anti-inflammatory soothing and barrier repair through a five-dimensional synergistic mechanism of 'barrier repair-immune tolerance-nerve desensitization-anti-inflammatory itching-moisturizing stability maintenance'; the introduction of ceramides, rare ginsenosides, plant sterol esters, and free fatty acids synergistically constructs 'bionic liposomes', which are closer to the lipid composition of human stratum corneum, enhance transdermal absorption and stability, and significantly improve repair efficiency; the synergistic effect of dipotassium glycyrrhizinate, tamarix flower extract, spilanthes extract, dinoxanthin, and baicalin suppresses rapid anti-inflammatory itching, strengthens barrier repair, and is suitable for highly sensitive skin.

This invention discloses a lipid composition, stock solution, preparation method, preparation system, and application for preparing broad-spectrum solvent-compatible liposomes. The lipid composition consists of HSPC, cholesterol, octadecylamine, and vitamin E polyethylene glycol succinate in specific proportions; it is dissolved in an aqueous organic solvent (such as ethanol) to form a lipid stock solution; the preparation system employs a three-channel intelligent control pump; in the preparation method, the above-mentioned lipid stock solution, an aqueous phase containing the target components (which can be pure water to 40% organic solvent-water solution), and a blank aqueous phase are injected into a microfluidic chip to generate a liposome dispersion, which is then purified. This invention overcomes the limitation of solvent polarity on liposome preparation, enabling the stable preparation of high-quality liposomes in a wide range of solvent systems. Experiments have shown that this liposome significantly enhances the stability and transdermal permeability of the encapsulated components, providing a universal, precise, and low-cost delivery platform for encapsulating various active ingredients.

The invention relates to a powder premixture for oral administration of cannabinoids, comprising a cannabinoid powder composition comprising one or more isolated cannabinoids in an amount of at least 2% by weight of the powder premixture; a lipid composition comprising one or more triglycerides in an amount of at least 1.0% by weight of the powder premixture; and a sweetener powder composition comprising one or more sweeteners, wherein the weight ratio between the one or more triglycerides and the one or more sweeteners is in the range of 1:50 to 1:4.